Healio Psoriatic Disease Current Issue
The following articles appeared in the print edition of Healio Psoriatic Disease.
Table of Contents
- Vaccines remain main aspect to COVID-19’s evolving landscape
-
- Bimzelx shows improvement in psoriatic arthritis Rebecca L. Forand
- COVID-19: Lessons learned for the path forward Joel M. Gelfand, MD, MSCE
- FDA approves Skyrizi for adults with active psoriatic arthritis Jason Laday
- Air pollution exposure may trigger psoriasis flares Rebecca L. Forand
- COVID-19 vaccine uptake higher among patients with IMIDs than general population Jason Laday
- Early response to ixekizumab, ustekinumab predicts long-term skin clearance in psoriasis Rob Volansky
- Epicardial adipose tissue volumes elevated in men with psoriasis Rob Volansky
- Hematological parameters can be used to assess psoriasis severity ‘to some extent’ Rebecca L. Forand
-
- Self-administering bimekizumab via syringe, auto-injector sees similar success, safety Rebecca L. Forand
- Specialist-led interventions may improve cardiovascular outcomes in psoriatic disease Rob Volansky
- Surge in specialty drug use ‘largely driven’ by autoimmune disease Jason Laday
- Tofacitinib exhibits shorter timeline to initial clinical response in PsA vs. placebo Jason Laday
- Use of analgesics in PsA patients warrants attention Rebecca L. Forand
- Guselkumab ranks high in psoriasis clearance among psoriatic arthritis treatments Rebecca L. Forand
- Roflumilast cream shows improvement in plaque psoriasis itch, severity Rebecca L. Forand